CB1 receptor blockers caused diarrhea so consistently they might actually treat constipation-dominant IBS
A meta-analysis of 18 clinical trials found that CB1 receptor inverse agonists (rimonabant and taranabant) consistently caused gastrointestinal side effects, particularly diarrhea, suggesting they could be repurposed for constipation-predominant IBS.
Quick Facts
What This Study Found
Rimonabant 20mg produced significantly more GI adverse events than placebo (OR 2.05) and overall adverse events (OR 1.35). Taranabant showed similar patterns (GI AEs OR 1.75, overall OR 1.36). Both drugs also caused significantly more psychiatric adverse events.
Key Numbers
18 trials analyzed. Rimonabant 20mg: GI AEs OR 2.05 (CI: 1.65-2.55, p<0.001), psychiatric AEs OR 1.79 (CI: 1.46-2.21). Taranabant 0.5-8mg: GI AEs OR 1.75 (CI: 1.29-2.37), psychiatric AEs OR 1.82 (CI: 1.54-2.16).
How They Did This
Systematic review and meta-analysis of 18 clinical trials published through May 2018 reporting at least one month of treatment with rimonabant or taranabant, analyzing gastrointestinal adverse events using odds ratios.
Why This Research Matters
IBS with constipation has limited treatment options. This creative approach of repurposing a known side effect (diarrhea from CB1 blockers) into a therapeutic benefit illustrates how understanding the endocannabinoid system's role in gut function could yield new treatments.
The Bigger Picture
Rimonabant was withdrawn from the market due to psychiatric side effects. However, peripherally-restricted CB1 antagonists that don't cross the blood-brain barrier could potentially deliver the gut effects without the psychiatric risks, opening a new avenue for IBS treatment.
What This Study Doesn't Tell Us
The trials analyzed were designed for obesity/metabolic conditions, not IBS. GI adverse events were secondary outcomes, not primary endpoints. Psychiatric side effects (which led to rimonabant's withdrawal) remain a barrier. No IBS-specific trials have been conducted.
Questions This Raises
- ?Could peripherally-restricted CB1 antagonists provide GI benefits without psychiatric side effects?
- ?What would be the optimal dose for IBS-C specifically?
- ?Would these agents be effective for other forms of constipation beyond IBS?
Trust & Context
- Key Stat:
- CB1 blockers doubled GI adverse events vs placebo (OR 2.05), suggesting therapeutic potential for IBS-C
- Evidence Grade:
- Strong: meta-analysis of 18 clinical trials with consistent findings across two different drugs.
- Study Age:
- Published in 2019, analyzing trials through May 2018.
- Original Title:
- Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.
- Published In:
- Journal of gastrointestinal and liver diseases : JGLD, 28(4), 473-481 (2019)
- Authors:
- Fabisiak, Adam(2), Włodarczyk, Marcin, Fabisiak, Natalia, Storr, Martin, Fichna, Jakub
- Database ID:
- RTHC-02026
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Could cannabinoid drugs help with IBS?
This meta-analysis suggests CB1 receptor blockers could help constipation-predominant IBS, based on their consistent diarrhea-causing effect. However, no IBS-specific trials have been conducted, and psychiatric side effects remain a concern.
Why were these drugs withdrawn if they could help IBS?
Rimonabant was withdrawn due to psychiatric side effects (anxiety, depression). Future research may focus on peripherally-restricted versions that act only in the gut without crossing into the brain.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-02026APA
Fabisiak, Adam; Włodarczyk, Marcin; Fabisiak, Natalia; Storr, Martin; Fichna, Jakub. (2019). Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.. Journal of gastrointestinal and liver diseases : JGLD, 28(4), 473-481. https://doi.org/10.15403/jgld-265
MLA
Fabisiak, Adam, et al. "Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.." Journal of gastrointestinal and liver diseases : JGLD, 2019. https://doi.org/10.15403/jgld-265
RethinkTHC
RethinkTHC Research Database. "Gastrointestinal Adverse Events of Cannabinoid 1 Receptor In..." RTHC-02026. Retrieved from https://rethinkthc.com/research/fabisiak-2019-gastrointestinal-adverse-events-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.